120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
ICS + LABA 联合治疗对哮喘控制的影响：真实世界环境下的观察性研究
Received 15 June 2025
Accepted for publication 24 November 2025
Published 7 February 2026 Volume 2026:22 547261
DOI https://doi.org/10.2147/TCRM.S547261
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Garry Walsh
Ping Han,1 Lihua Wang2
1Department of Pharmacy, Wuhan Hankou Hospital, Wuhan, Hubei, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, Wuhan Dongxihu District People’s Hospital, Wuhan, Hubei, People’s Republic of China
Correspondence: Lihua Wang, Department of Respiratory and Critical Care Medicine, Wuhan Dongxihu District People’s Hospital, No. 48, Jinbei 1st Road, Jinghe Street, Dongxihu District, Wuhan, Hubei, 430040, People’s Republic of China, Email wanglihua3050@163.com
Background: Inhaled corticosteroids (ICS) combined with long-acting β 2-agonists (LABAs) remain the cornerstone of maintenance therapy in persistent asthma. Although multiple trials have demonstrated short-term efficacy, there is a lack of comprehensive, long-term data on the impact of ICS/LABA therapy on asthma control, exacerbation frequency, and pulmonary function in real-world clinical settings. This study aims to fill this gap by evaluating the effects of ICS/LABA therapy over a 24-month period in a real-world cohort.
Methods: We conducted a retrospective cohort study involving 237 adult patients with moderate-to-severe persistent asthma treated at Wuhan Hankou Hospital between January 2021 and December 2023. Eligible participants had ≥ 12 months of documented ICS/LABA use. Patients were evaluated for asthma control using the Asthma Control Test (ACT), frequency of acute exacerbations requiring systemic corticosteroids, pulmonary function (FEV1 % predicted), and adverse drug reactions. Data were collected at baseline, 12 months, and 24 months.
Results: After 24 months, the proportion of patients achieving well-controlled asthma (ACT ≥ 20) increased significantly from 42.6% at baseline to 73.0% (P < 0.001). Mean FEV1 improved from 72.1 ± 10.4% to 79.8 ± 11.2% predicted (P = 0.002). The annualized exacerbation rate declined from 2.1 ± 1.0 to 0.8 ± 0.6 episodes per patient (P < 0.001). Medication adherence, defined as ≥ 80% refill rate, was significantly associated with greater improvements in ACT and FEV1. Reported side effects included oropharyngeal candidiasis (8.0%), dysphonia (5.1%), and tremors (3.8%), but no serious adverse events were documented.
Conclusion: Continuous use of inhaled corticosteroids in combination with long-acting β-agonists was associated with sustained improvements in asthma control, enhanced lung function, and a reduction in the frequency of exacerbations. These findings support the continued use of ICS/LABA therapy as an effective and safe strategy for long-term asthma management in clinical practice.
Keywords: asthma, inhaled corticosteroids, long-acting β 2-agonists, long-term outcomes, lung function, exacerbation, asthma control test
1Department of Pharmacy, Wuhan Hankou Hospital, Wuhan, Hubei, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, Wuhan Dongxihu District People’s Hospital, Wuhan, Hubei, People’s Republic of China
Correspondence: Lihua Wang, Department of Respiratory and Critical Care Medicine, Wuhan Dongxihu District People’s Hospital, No. 48, Jinbei 1st Road, Jinghe Street, Dongxihu District, Wuhan, Hubei, 430040, People’s Republic of China, Email wanglihua3050@163.com
Background: Inhaled corticosteroids (ICS) combined with long-acting β 2-agonists (LABAs) remain the cornerstone of maintenance therapy in persistent asthma. Although multiple trials have demonstrated short-term efficacy, there is a lack of comprehensive, long-term data on the impact of ICS/LABA therapy on asthma control, exacerbation frequency, and pulmonary function in real-world clinical settings. This study aims to fill this gap by evaluating the effects of ICS/LABA therapy over a 24-month period in a real-world cohort.
Methods: We conducted a retrospective cohort study involving 237 adult patients with moderate-to-severe persistent asthma treated at Wuhan Hankou Hospital between January 2021 and December 2023. Eligible participants had ≥ 12 months of documented ICS/LABA use. Patients were evaluated for asthma control using the Asthma Control Test (ACT), frequency of acute exacerbations requiring systemic corticosteroids, pulmonary function (FEV1 % predicted), and adverse drug reactions. Data were collected at baseline, 12 months, and 24 months.
Results: After 24 months, the proportion of patients achieving well-controlled asthma (ACT ≥ 20) increased significantly from 42.6% at baseline to 73.0% (P < 0.001). Mean FEV1 improved from 72.1 ± 10.4% to 79.8 ± 11.2% predicted (P = 0.002). The annualized exacerbation rate declined from 2.1 ± 1.0 to 0.8 ± 0.6 episodes per patient (P < 0.001). Medication adherence, defined as ≥ 80% refill rate, was significantly associated with greater improvements in ACT and FEV1. Reported side effects included oropharyngeal candidiasis (8.0%), dysphonia (5.1%), and tremors (3.8%), but no serious adverse events were documented.
Conclusion: Continuous use of inhaled corticosteroids in combination with long-acting β-agonists was associated with sustained improvements in asthma control, enhanced lung function, and a reduction in the frequency of exacerbations. These findings support the continued use of ICS/LABA therapy as an effective and safe strategy for long-term asthma management in clinical practice.
Keywords: asthma, inhaled corticosteroids, long-acting β 2-agonists, long-term outcomes, lung function, exacerbation, asthma control test